CTLA4 as a major candidate gene for AA susceptibility in humans (John et al., 2011) , providing exciting data on human AA and validating the first bona fide susceptibility locus outside the HLA. The co-stimulatory locus containing the CTLA4 gene on mouse chromosome 1 (human chromosome 2) was not previously identified as a quantitative trait locus in the mouse AA model (Sundberg et al., 2003; Sundberg et al., 2004) . However, the convergence of expression data from the AA model with the human studies confirm our hypothesis that antigen presentation in association with CTLA4 -CD80/86 co-stimulation is implicated in the development of AA and provides a crucial foundation for future human clinical studies. For example, the preclinical data from the mouse AA model could be used to support testing of Abatacept (Orencia®), a drug approved by the FDA to treat autoimmune rheumatoid arthritis (Moreland et al., 2006) , as a safe and effective therapy for human AA. Abatacept is a fusion protein with the extracellular domain of CTLA4 fused with the hinge CH2 and CH3 domains of human IgG1. It is a selective modulator that binds to the co-stimulatory protein CD28 on T cells and B7 proteins (CD80/CD86) on APCs. As a possible alternative, Ipilimumab (Yervoy®) is a fully humanized anti-CTLA4 monoclonal antibody FDA approved to treat metastatic melanoma; however, Ipilimumab has been documented to induce human autoimmune diseases in clinical use (Callahan et al., 2010) while Abatacept has not so far. Abatacept is associated with an increased incidence of infections due to its immunosuppressive effects (Dubois and Cohen, 2009) , but this may be acceptable to AA patients if it is shown to be efficacious for hair growth.
Why is there a delay in a detailed exploration of the CTLA4 pathway(s) in human AA? A lingering bias against animal models of human disease is widespread in the medical and lay community, partly based on the not uncommon lack of treatment efficacy confirmation and/or safety issues revealed in subsequent human clinical trials. The explosion of genetic analyses studies shows that at a cellular and genetic level there are many common regulatory pathways in human diseases and their respective animal models. When findings in a putative animal model for a specific human disease do not fulfill all the precise features of the human disease it most likely means that: 1) the original model selection was flawed or the human disease is incompletely or incorrectly characterized, 2) the human disease is heterogenic due to genetic, ethnic, age, and gender differences in the disease susceptibility and/or variations in environmental influence; issues that cannot always be replicated with inbred animal models in a regulated environment, or 3) the methodology in the model studies or subsequent human trials was flawed leading to systematic bias (van der Worp et al., 2010) . The challenge in developing any new therapy for human diseases involves the careful selection of a suitable preclinical model(s) to be used and well-defined human subjects to be evaluated. While such issues cannot be ignored, the identification of a relevant animal model for a human disease can prove invaluable for studying disease mechanisms and for developing and screening new treatments.
The discoveries made in humans, rats, and mice with AA over the past 20 years led to understanding just how complex its genetics, molecular mechanisms, and its molecular pathways are (Carroll et al., 2002; Subramanya et al., 2010) in regulating its susceptibility, progression, and resolution (John et al., 2011; Petukhova et al., 2010; Sundberg et al., 2003; Sundberg et al., 2004) . Autoimmunity in humans and other mammals have many biological and genetic features that share many common regulatory pathways and provide valid insights (Sundberg and Schofield, 2009) . Though the AA models are not perfect representations of human AA, the fundamental concepts of AA in rodents and humans have proven remarkably similar thus far. By integrating findings from multiple sources, great advances will continue to assist in developing safe and effective treatments for human and animal diseases including AA.
